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ABSTRACT
Objectives: This study assessed patient preferences,
using willingness to pay as a method to measure
different treatment characteristics or attributes
associated with injectable insulin therapy in patients
with type 2 diabetes.
Research design and methods: Adults with type 2
diabetes in 12 countries, diagnosed >6 months prior
and receiving insulin for >3 months, were recruited
through a representative online panel. Data were
collected via online questionnaire and analyzed using a
standard choice model for discrete choice experiment.
Results: A total of 3758 patients from North America
(n=646), South America (n=1537), and Europe
(n=1575) completed the study. Mean glycated
hemoglobin (HbA1c) levels in North America, South
America, and Europe were 63 mmol/mol (7.9%),
75 mmol/mol (9.0%), and 64 mmol/mol (8.0%),
respectively. In the three regions, monthly willingness
to pay was US$116, US$74, and US$92, respectively,
for a 1%-point decrease in HbA1c; US$99, US$80, and
US$104 for one less major hypoglycemic event per
year; and US$64, US$37 and US$60 for a 3 kg weight
decrease. To avoid preinjection preparation of insulin,
the respective values were US$47, US$18, and US$37,
and US$25, US$25, and US$24 for one less injection
per day. Among respondents on basal-only insulin
who had previously tried a more intensive regimen,
reasons for switching back included difficulty in
handling multiple injections and risk of hypoglycemic
events.
Conclusions: Reducing HbA1c, frequency of major
hypoglycemic events and weight decrease were the
highest valued outcomes in each region. The
administrative burden of injections was also considered
important.
INTRODUCTION
The economic and clinical burden of dia-
betes is large, both for healthcare systems,
and the individuals and their families living
with diabetes.1 In 2013, 382 million people
worldwide were estimated to have diabetes,
of which 90% had type 2 diabetes.1 2
Globally, healthcare costs to manage diabetes
and its complications totaled US$548 billion
in 2013, equivalent to 11% of total worldwide
health expenditure.1
Recommended glycemic goals are achieved
by less than 50% of people with type 2 dia-
betes.3–6 Contributing to this are negative
patient beliefs about the efﬁcacy and safety
of medication, and increasing complexity of
therapies that may produce barriers to
insulin treatments and may have an impact
on medication adherence.4 7 8 Poor glycemic
control has a longer term impact on clinical
outcomes and associated costs, as well as
short-term effects on patient symptoms and
quality of life.9 As such, it is important to
understand how people with type 2 diabetes
perceive the management of their condition
and what they will accept in terms of impact
on their daily lives. This may assist treatment
strategies and support patient adherence.
Patient preferences for treatments have
been shown to inﬂuence adherence to treat-
ment in type 2 diabetes, affecting glucose
lowering efﬁcacy and overall burden of
disease.3 10–12 For instance, it is likely that
some people with diabetes already make
preference decisions on aspects, or attri-
butes, of their treatment, for example,
accepting poorer glycemic control and a
higher risk of long-term complications in
return for fewer episodes of hypoglycemia.13
Key messages
▪ Assessing willingness to pay can be used to
understand patient preference for different treat-
ment characteristics or attributes of injectable
insulin therapy for type 2 diabetes.
▪ Reducing glycated hemoglobin, fewer major
hypoglycemic events and weight decrease were
the characteristics/attributes of injectable insulin
therapy valued highest by respondents.
▪ Respondents on basal-only insulin who had pre-
viously tried a more intensive regimen cited diffi-
culty in handling multiple injections, risk of
weight gain, and risk of hypoglycemic events as
the reasons for reverting to basal-only.
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One method of assessing patient preference for differ-
ent treatment characteristics (attributes) is by measuring
willingness to pay (WTP). WTP is deﬁned as the amount
of money an individual is willing to give up in order to
procure goods or a service.14 15 It can be derived from
discrete choice experiments3 16 based on two key prem-
ises that (1) treatments can be described by their
characteristics (attributes), and (2) the extent to which
an individual values the treatment depends on the
nature and levels of these characteristics. This is particu-
larly relevant for people who require treatment intensiﬁ-
cation as the disease progresses, in order to maintain
glycemic control. Measurement of WTP in diabetes has
been demonstrated previously via discrete choice experi-
ments in several studies.3 11 17 This approach allows the
relative importance of treatment attributes and the
respondents’ WTP to obtain or avoid attributes to be
determined.18 This provides insight into which
characteristics of a treatment regimen would most likely
be preferred by people with type 2 diabetes.18
Data from large studies investigating WTP in type 2
diabetes are limited. The current study, using method-
ology similar to that used by Bogelund et al,3 was con-
ducted in 12 countries across North and South America
and Europe, making it the largest WTP study to date.
The study aimed to investigate patient preferences
for different clinical outcomes and administration
burden of insulin treatments, and to assess a measure-
ment of respondents’ WTP for several aspects of treat-
ment or attributes related to injectable insulin therapy,
with assessment of the relative importance of each
attribute.
METHODS
Patients
Patients were recruited from a web-based panel derived
from members recruited via telephone or online adver-
tisements. Patients consented to participate and involve-
ment in the study was voluntary. Respondents were
required to have been diagnosed with type 2 diabetes
>6 months and be receiving subcutaneous injection of
insulin for >3 months but not via pump therapy. Data
were collected between August 2014 and February 2015
from respondents in North America (USA and Canada),
South America (Chile, Colombia, Brazil, Argentina, and
Mexico) and Europe (UK, France, Italy, Germany, and
the Netherlands).
Design
The study was a cross-section study design. Six focus
groups were conducted to gain insights into the daily
life of people with type 2 diabetes, and to identify and
validate the relevant diabetes treatment attributes for
inclusion in the survey. The focus groups were held in
Manchester, UK (n=4; n=6), Paris, France (n=6; n=7 plus
2 individual interviews), and Philadelphia, USA (n=7;
n=8). Participants were asked to discuss the aspects of
diabetes treatment relevant to them, and to rank these
aspects according to importance in their daily life.
Participants also gave recommendations on how to
describe each aspect to ensure relevance for people with
diabetes. Finally, they were asked to assign values to spe-
ciﬁc improvements in each aspect. These ﬁndings were
consolidated across the three regions and the most
important features for patients with diabetes were
selected as the attributes for inclusion in the online
study questionnaire.
The questionnaire took approximately 15 min to com-
plete and comprised six sections: (1) patient demo-
graphics; (2) attitudes of people with type 2 diabetes
towards diabetes; (3) current and target HbA1c; (4)
hypoglycemic events; (5) previous and current treatment
and perceptions; and (6) WTP. This section was con-
structed around the core aspects of treatment or attri-
butes, with a set of associated levels assigned to each
attribute based on insights from the focus groups
(table 1). Hypoglycemic events were deﬁned as either
‘major’, if requiring assistance from another person to
effect recovery; or ‘minor’, estimated to account for 88–
98% of all events,19–21 and deﬁned by the ability to
self-treat.22 23
The descriptive levels for each attribute were deter-
mined based on insights from the focus groups. The
degree of reduction in HbA1c and weight was assigned
according to standard clinical practice.
The descriptive levels for minor and major hypogly-
cemic events were based on insights from the focus
groups and a previous study by Evans et al.24 The
descriptive levels for the other attributes (number of
injections and preparation of insulin by rolling and
inverting pen or vial) were determined by treatment
guidelines for use of insulin. The levels for the payment
attributes were based on the focus groups and results
from Jendle et al.16
From all possible combinations of attribute levels, a
series of choice sets was derived using balanced, orthog-
onal, fractional, factorial design, generated using the
Ngene discrete choice experimental design software
system (developed by Choice Metric Pty Ltd)—see
table 1 for an example.
This approach ensured parameter estimates were
uncorrelated and could be determined independently
of other attributes, and attribute levels occurred with
equal frequency within the proﬁles, thus supporting
robust results for all levels.
Each choice set presented attributes and levels for two
different hypothetical diabetes treatments with payment
levels documented as direct ‘out of pocket’ costs per
month. Respondents were asked to select the preferred
treatment option within each scenario, providing a hypo-
thetical trade-off, which formed the basis of the analysis.
In order to maximize the information gathered from
the respondents, each respondent was randomly
assigned to one of four blocks of these questions, each
block consisting of nine choice sets.
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The inclusion of a test question presenting a scenario
with one proﬁle better than the others for all attributes
—that is, no trade-off required—ensured respondents
understood the overall concept of ‘trade-off’.
Respondents are likely to have different preferences for
certain attributes. Therefore, in the choice set used for
the test question, only the number of minor and major
hypoglycemic events, and the level of payment, were dif-
ferent in the two treatment proﬁles. As per published
practice,25 any respondents not selecting the superior
proﬁle were excluded. In this instance, respondents
choosing the treatment with both a higher number of
hypoglycemic events and a higher payment were
excluded.
The questionnaire was developed in English, and
translated using forward and backwards translation to
the native languages of the countries included in the
survey. The study was performed according to the
Declaration of Helsinki w/c 14 December 2014, and
anonymity of respondents was preserved in accordance
with European Society for Opinion and Marketing
Research, and European Pharmaceutical Market
Research Association regulations.26 27 Ethical approval
was obtained from Institutional Review Board Services,
Canada. Monetary values recorded in other currencies
were converted to US$ for reporting, using the
exchange rates prevalent in December 2014.28
Analysis
Data were validated and checked for consistency and
error before conducting the statistical analyses with the
SAS analytical software package (V.9.4, SAS Institute Inc,
North Carolina, USA). WTP for the different attributes
was determined using a standard mixed multinomial
logit model approach. The probability of choosing one
option ‘j’ from ni in a choice scenario (where there are
ni=2 possible options in each scenario choice set Ci) is
deﬁned by the equation3 29
P( j) ¼ exp (x
0
ijb)
P
k[Ci exp (x
0
ikb)
The estimated parameters b, will express preference
weights for each attribute level. The WTP values for the
Table 1a Clinical and convenience attributes related to insulin treatment; Table 1b Typical scenario choice sets for WTP
1a Core attributes Levels for each attribute
Change in HbA1c ▸ 1%-point reduction in HbA1c
▸ No change
Number of minor hypoglycemic events ▸ 52 per year
▸ 12 per year
▸ 4 per year
▸ 0 per year
Number of major hypoglycemic events (per 12 months) ▸ 1 per year
▸ 0 per year
Preparation of insulin (rolling and inverting the pen or vial) ▸ Preparation of insulin
▸ No preparation of insulin
Number of injections per day ▸ 1 injection per day
▸ 2 injections per day
▸ 4 injections per day
Change in weight ▸ Weight increase of 1 kg
▸ Remain the same weight
▸ Weight decrease of 3 kg
▸ Weight decrease of 5 kg
Payment per month (out-of-pocket expense) ▸ US$27.75
▸ US$61.05
▸ US$127.65
▸ US$277.50
1b Typical WTP scenario choice sets
Treatment A Treatment B
HbA1c levels No change Reduction of 1%
Number of minor hypos 0 yearly 52 yearly
Number of major hypos 1 yearly 0 yearly
Weight change No change Lose 3 kg
Preparation of insulin before injection (rolling and inverting the pen or vial) No Yes
Number of insulin injections 1 daily injection 4 daily injections
Payment per month (out-of-pocket US$277.50 US$61.05
Which treatment do you prefer?
HbA1c, glycated hemoglobin; WTP, willingness to pay.
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attribute levels were calculated by dividing the estimated
coefﬁcients, β, for each attribute, by the coefﬁcient of
payment. The rationale underlying this approach was
derived from the economic theory of demand, in which
these calculated ratios are known as marginal rates of
substitution.30
The linearity of the relevant attributes was then tested
using a standard likelihood ratio test. This was the case
for weight loss, minor hypoglycemia events and number
of daily insulin injections. All these attributes exhibited
linearity and so the linear function was introduced into
the basic model. Interaction effects were tested accord-
ing to a predeﬁned statistical analysis plan. The results
for the linear variables were then subsequently calcu-
lated per unit, for example, WTP for a weight loss of
1 kg or 2 kg. Owing to the sample size required for
robust analysis, WTP data were assessed by region only.
The costs used in the discrete choice experimental
design were presented using the currency of each
country. When converting the currencies, the levels of
payment were corrected for purchasing power in each
country.
Since WTP data are calculated as the ratio between
two stochastic variables, CIs cannot be derived directly
from the parameter estimates of the conditional logit
estimations. Therefore, an adapted bootstrapping meth-
odology was applied—a method originally developed to
derive the estimate of SE of an arbitrary estimator.31 The
bootstrap methodology simulates the results from a
random sample of the actual data available.32 Empirical
research suggests that the best results are obtained when
the repeated samples are the same size as the original
sample and therefore the repetition is performed with
replacement.32 For deriving the CIs for current WTP
results, 10 000 iterations were carried out.32
The WTP design and analysis were performed in
accordance with the International Society for
Pharmacoeconomics and Outcomes Research Good
Practice for Conjoint Analysis in Health.33 34
RESULTS
Participants
Results from 3758 respondents with type 2 diabetes were
available for analysis, representing North America (USA
and Canada; n=646), South America (Brazil, Chile,
Colombia, Argentina, and Mexico; n=1537), and Europe
(UK, Germany, the Netherlands, Italy, and France;
n=1575).
Participants’ mean age in the three regions ranged
between 48.1 and 54.5 years, with the majority of respon-
dents being male in all three regions. The mean values
for duration with diabetes, duration on insulin, and
BMI, are presented by region in table 2 along with socio-
demographic characteristics across the three regions.
In all three regions, basal-only insulin was the most fre-
quently used insulin regimen, followed by basal-bolus
insulin. Few respondents were on bolus-only and premix-
only treatment schemes. Full details of the type of
insulin used are reported in table 2.
Payment for insulin
In North America, the majority of respondents paid for
at least some of their medication costs; in contrast, most
respondents in Europe indicated that they made no
payment. In South America, approximately half paid for
their medication. Full details about payment for medica-
tion are reported in table 2.
HbA1c levels
Approximately two-thirds of respondents in each region
were aware of their HbA1c levels, with a slightly lower
percentage being aware of their target HbA1c. The
mean reported HbA1c levels in North America, South
America, and Europe, were 63 mmol/mol (7.9%),
75 mmol/mol (9.0%) and 64 mmol/mol (8.0%),
respectively.
Hypoglycemic events
Full details pertaining to HbA1c levels and hypoglycemic
events are presented by region in table 2.
Barriers to treatment intensification
A proportion of respondents had reverted back to
basal-only insulin from an intensiﬁed regimen. In North
America, most had switched back from basal-bolus
insulin (52.6% (41/78)), followed by 38.5% (30/78)
from premixed insulin, and 9.0% (7/78) from basal
insulin plus a glucagon-like peptide receptor antagonist
(GLP-1 RA; table 3). In South America this was 57.8%
(115/199), 32.7% (65/199), and 9.5% (19/199),
respectively, with 48.8% (79/162), 37.7% (61/162), and
13.6% (22/162) in Europe.
Difﬁculty in handling multiple injections as well as risk
of weight gain and hypoglycemia were the most fre-
quently cited reasons for reverting back to basal-only
therapy. An analysis of patients with type 2 diabetes who
had reverted to basal-only insulin after previously switch-
ing to basal-bolus, premix insulin or a GLP-1 RA in com-
bination with basal insulin, is shown in table 3.
Analysis of willingness to pay
Results of the WTP analysis are presented in ﬁgure 1 as
monetary values per month. All treatment attributes were
signiﬁcant predictors of choice (p<0.05), with high mon-
etary values placed on efﬁcacy and safety outcomes. In
North America, respondents were willing to pay US$116
for a 1%-point decrease in HbA1c (95% CI (79 to 158)).
In South America, this was US$74 (CI (54 to 97)), with
US$92 (CI (69 to 117)) in Europe. WTP for ‘one less
major hypoglycemic event per year’ was US$99 (95% CI
(67 to 136)), US$80 (CI (62 to 102)), and US$104 (CI
(84 to 128)), and for ‘one less minor hypoglycemic event
per month’, WTP was US$34 (CI (25 to 43)), US$21 (CI
(16 to 26)), and US$22 (CI (17 to 28)) in North
America, South America, and Europe, respectively. WTP
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Table 2a Baseline characteristics of study respondents; Table 2b Glycemic control and hypoglycemia
Category All regions n (%) North America n (%) South America n (%) Europe n (%)
Table 2a
Clinical
Male/female 58.0% 57.7 54.1% 61.9%
Mean age (years) 51.4 54.5 48.1 53.4
Mean duration with diabetes
(years)
10.7 12.4 9.8 11.0
Mean duration with insulin (years) 5.7 6.4 4.8 6.3
Mean BMI(kg/m2) 30.3 33.5 29.1 30.3
Live alone 21.1% 29.6% 12.9% 25.7%
Have children 74.8% 60.5% 83.8% 71.8%
Married or partnered 68.7% 62.7% 68.1% 71.6%
College/university degree 46.1% 44.1% 52.0% 41.2%
In paid employment or
self-employed
37.6% 32.0% 40.1% 37.3%
Monthly household income before
tax=<approximately ≤US$3 000
31.5%* 32.8% 28.0%* 34.5%†
Type of insulin used
Basal insulin only 1841 (49.0%) 274 (42.4%) 963 (62.7%) 604 (38.4%)
Bolus insulin only 490 (13.0%) 59 (9.1%) 166 (10.8%) 265 (16.8%)
Basal and bolus insulin 1020 (27.1%) 224 (34.7%) 274 (17.8%) 522 (33.1%)
Premixed only 332 (8.8%) 70 (10.8%) 106 (6.9%) 156 (9.9%)
Other combination 75 (2.0%) 19 (2.9%) 28 (1.8%) 28 (1.8%)
Payment of medication
Yes, I pay for all of it 657 (17.5%) 123 (19.0%) 391 (25.4%) 143 (9.1%)
Yes, I pay for some of it 1011 (26.9%) 335 (51.9%) 382 (24.9%) 294 (18.7%)
No, I don’t pay for any of it 2090 (55.6%) 188 (29.1%) 764 (49.7%) 1138 (72.3%)
Table 2b
HbA1c
HbA1c and patient awareness
Number of respondents
knowing their HbA1c
2441 (65.0%) 395 (61.2%) 964 (62.7%) 1082 (68.7%)
Respondents’ mean HbA1c 67 mmol/mol (8.3%) 63 mmol/mol (7.9%) 75 mmol/mol (9.0%) 64 mmol/mol (8.0%)
Number of respondents who
are aware of target HbA1c
2308 (61.4%) 392 (60.7%) 909 (59.1%) 1007 (63.9%)
Hypoglycemic events
Have respondents ever experienced a minor hypoglycemic event?
Yes 2950 (78.5%) 500 (77.4%) 1202 (78.3%) 1248 (79.2%)
Frequency of minor hypoglycemic events
3 times weekly 256 (8.7%) 31 (6.2%) 112 (9.3%) 113 (9.1%)
Once weekly 757 (25.7%) 109 (21.8%) 323 (26.9%) 325 (26.0%)
Once monthly 805 (27.3%) 147 (29.4%) 317 (26.4%) 341 (27.3%)
Once every 3 months 420 (14.2%) 87 (17.4%) 163 (13.6%) 170 (13.6%)
Less than once every 3 months 712 (24.1%) 126 (25.2%) 287 (23.9%) 299 (24.0%)
Never 710 (18.9%) 119 (18.4%) 294 (19.1%) 297 (18.9%)
Mean number of events yearly 25.0 20.8 26.2 25.5
Have respondents ever experienced a major hypoglycemic event?
Yes 929 (24.7%) 178 (27.6%) 345 (22.5%) 406 (25.8%)
Number of major hypoglycemic events during the past 12 months
0 2754 (73.3%) 446 (69.0%) 1148 (74.7%) 1160 (73.7%)
1–2 391 (10.4%) 69 (10.7%) 137 (8.9%) 185 (11.7%)
3–4 166 (4.4%) 44 (6.8%) 47 (3.1%) 75 (4.8%)
5–6 75 (2.0%) 13 (2.0%) 23 (1.5%) 39 (2.5%)
7–8 24 (0.6%) 8 (1.2%) 4 (0.3%) 12 (0.8%)
9–10 49 (1.3%) 9 (1.4%) 21 (1.4%) 19 (1.2%)
More than 10 108 (2.9%) 14 (2.2%) 60 (3.9%) 34 (2.2%)
*The number for South America is an estimate, since different country-specific currencies were used.
†The value for Europe is based on the % of respondents with a monthly household income of ≤€1999.
BMI, body mass index; HbA1c, glycated hemoglobin level.
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for a 1 kg weight decrease was US$21 (CI (14 to 29)),
US$12 (CI (8 to 16), and US$20 (CI (15 to 25)) in North
America, South America, and Europe, respectively. For a
2 kg weight decrease, WTP was US$43 (CI (27 to 59)),
US$25 (CI (17 to 33)), and US$40 (CI (31 to 50)),
respectively, while for 3 kg decrease, WTP was US$64 (CI
Table 3 Patients with type 2 diabetes currently using basal insulin, previously intensified with bolus or GLP-1 RA, or
premixed insulin
Patients with type 2 diabetes
Region
All regions North America South America Europe
Total number of respondents 439 78 199 162
Previously added bolus to basal insulin
Number of patients 235 (53.5%) 41 (52.6%) 115 (57.8%) 79 (48.8%)
Reasons for going back to basal insulin only
Difficult to handle multiple injections 26.4% 29.3% 27.8% 22.8%
Risk of weight gain 25.1% 39.0% 17.4% 29.1%
Risk of hypoglycemia events 23.8% 24.4% 20.9% 27.9%
Difficult to calculate bolus dose 22.1% 14.6% 25.2% 21.5%
Other reasons 21.3% 22.0% 22.6% 19.0%
Previously added GLP-1 RA to basal insulin
Number of patients 48 (10.9%) 7 (9.0%) 19 (9.5%) 22 (13.6%)
Reasons for going back to basal insulin only
Difficult to handle multiple injections 29.2% 42.9% 31.6% 22.7%
Risk of hypoglycemic events 31.3% 0.0% 52.6% 22.7%
Risk of gastrointestinal (GI) side effects 18.8% 0.0% 26.3% 18.2%
Other reasons 31.3% 57.1% 10.5% 40.9%
Previously switched to premixed insulin
Number of patients 156 (35.5%) 30 (38.5%) 65 (32.7%) 61 (37.7%)
Reasons for going back to basal insulin only
Difficult to handle multiple injections 49.4% 36.7% 61.5% 42.6%
Risk of weight gain 34.6% 26.7% 27.7% 45.9%
Risk of hypoglycemic events 17.3% 20.0% 23.1% 9.8%
Other reasons 11.5% 23.3% 4.6% 13.1%
GLP-1 RA, glucagon-like peptide receptor antagonist.
Figure 1 Willingness to pay (WTP) for clinical outcomes in separate regions: (A) (North America) (B) (South America) and (C)
(Europe). HbA1c, glycated hemoglobin.
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(41 to 88)), US$37 (CI (25 to 49)), and US$60 (CI (46 to
75)). Additionally, in order to avoid preparation of
insulin (eg, rolling and inverting the pen or vial), respon-
dents were willing to pay US$47 (CI (12 to 83)), US$18
(CI (−0.27 to 37)), and US$37 (CI (15 to 59)), respect-
ively. For one less injection per day, WTP was US$25 (CI
(12 to 38)), US$25 (CI (18 to 33)), and US$24 (CI (16 to
33)), in North America, South America, and Europe,
respectively.
An alternative way to present the outcomes of the ana-
lysis is by assessing the WTP of each attribute relative to
one consistent attribute. In North America, comparing
against ‘reduction of minor hypoglycemic events per
month by one’, a 1%-point decrease in HbA1c was
valued 3.4 times higher (US$116 vs US$34); one less
major hypoglycemic event per year 2.9 times higher
(US$99 vs US$34); being able to avoid preparation of
insulin 1.4 times higher (US$47 vs US$34), and a 3 kg
decrease in weight 1.9 times higher (US$64 vs US$34).
Also, WTP for one less minor hypoglycemic event per
month was 1.4 times more than WTP for one less injec-
tion per day (US$34 vs US$25).
In South America, comparing against ‘reduction of
minor hypoglycemic events per month by one’, a
1%-point decrease in HbA1c was valued 3.5 times higher
(US$74 vs US$21); one less major hypoglycemic event
per year 3.8 times higher (US$80 vs US$21); a 3 kg
decrease in weight 1.8 times higher (US$37 vs US$21),
and one less injection per day 1.2 times higher (US$25
vs US$21). Additionally, one less minor hypoglycemic
event per month was valued 1.2 times higher than being
able to avoid preparation of insulin (US$21 vs US$18).
In Europe, comparing against ‘reduction of minor
hypoglycemic events per month by one’, a 1%-point
decrease in HbA1c was valued 4.2 times higher (US$92
vs US$22); one less major hypoglycemic event per year
4.7 times higher (US$104 vs US$22); being able to avoid
preparation of insulin 1.7 times higher (US$37 vs
US$22); one less injection per day 1.1 times (US$24 vs
US$22), and a 3 kg decrease in weight was valued 2.7
times higher (US$60 vs US$22).
DISCUSSION
To the best of our knowledge, this is the largest pub-
lished international study reporting willingness to pay
for different treatment attributes in type 2 diabetes care
and outcomes related to subcutaneous injection of
insulin. The results demonstrated the relative values
people with type 2 diabetes place against different attri-
butes of treatment. The principle ﬁndings showed that
treatment attributes were signiﬁcant predictors of choice
(p<0.05), with high monetary values placed on efﬁcacy
and safety outcomes. Respondents on basal-only insulin
who had previously tried a more intensive regimen
switched back citing the reasons as difﬁculty in handling
multiple injections, risk of weight gain, and risk of hypo-
glycemic events.
Demographic split in the study population was in line
with global data, with a slightly higher proportion of
males. The reported frequency of hypoglycemic events is
similar to previous ﬁndings of Bogelund et al3 in
Denmark. Additionally, the estimated annual rate of
major hypoglycemic events in people with type 2 dia-
betes was measured by the HAT study at 2.5 events per
year, while in the current study, at least one major hypo-
glycemic event was experienced by 22% of respondents
across all regions during the past 12 months.35 Unlike
previous studies, the current study presented data for
both, major and minor hypoglycemic events, allowing
demonstration of the relative value attributed to each.
Based on the results, avoidance of major hypoglycemic
events is most highly valued in Europe and South
America relative to the other attributes. In North
America, WTP valuation was highest for a 1%-point
reduction in HbA1c. Overall, nearly half of the respon-
dents were taking basal-only insulin, accounting for the
largest treatment population across all three regions. Of
these, nearly a quarter of the respondents had reverted
back to basal-only insulin following previous treatment
intensiﬁcation. Among the perceived barriers investi-
gated, the number of daily injections, the risk of hypo-
glycemic events, and the risk of weight gain, were most
frequently noted as reasons for discontinuing and revert-
ing back to basal insulin. This supported the ﬁndings of
the WTP analysis in that people with type 2 diabetes are
keen to avoid the perceived negative outcomes of inten-
sifying their insulin treatment. With regard to the
number of daily injections, the WTP valuation for one
less injection per day may appear relatively low. However,
patients may potentially administer several injections on
a daily basis, so considering only one less injection may
not appear to be of great importance initially.
The current ﬁndings support those from country spe-
ciﬁc studies in Sweden16 and Denmark3 that include
people with type 2 diabetes value improvements in treat-
ment proﬁle, and the resulting health and lifestyle bene-
ﬁts. The present results are also consistent with those
from Lloyd et al,36 where avoidance of hypoglycemia or
weight gain, and the reduction in the number of daily
injections, were associated with positive WTP values rela-
tive to other attributes. For instance, WTP in North
America for one less major hypoglycemic event per year,
to decrease weight by 1 kg, and to administer one less
injection per day, is US$99, US$21 and US$25 per
month, respectively. In the US study by Hauber et al,17
the reduction in average glucose (HbA1c) is valued most
highly by respondents, which is reﬂected by ﬁndings in
this study, where respondents from North America were
most willing to pay for a 1%-point decrease in HbA1c
(US$116 per month). This was also consistent with ﬁnd-
ings in Denmark,3 where the WTP was €99 per month
for the same attribute (US$126 per month, using
December 2014 exchange rate28). WTP varied across the
different attributes. However, as WTP is the patients’
best assessment of the value, these may differ from real
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life situations and it is likely that the relativeness
between WTP values will provide a better indication of
the relative importance of each attribute. For instance,
in North America, ‘one less minor hypoglycemic event
per month’ was valued low in comparison to the value
of a 3 kg decrease in weight (US$34 per month vs
US$64 per month). However, despite a relatively low
WTP, minor hypoglycemic events are associated with a
reduction in quality of life,37 38 and can interrupt and
affect the ability to carry out day-to-day tasks.39 It may
therefore be relevant to further analyze how patients
value other clinical aspects compared to minor hypogly-
cemic events. In contrast, ‘one less major hypoglycemic
event per year’ was valued high in comparison with
other attributes, and valued at the same level as redu-
cing HbA1c by 1%-point. The difference between
regions in terms of the attribute that was valued the
most by respondents is another area of particular inter-
est; respondents from North America valued a 1%-point
reduction in HbA1c the highest, compared to Europe,
where a reduction in major hypoglycemic events was
most valuable. Speciﬁc treatment scenarios demonstrat-
ing the applicability of the study ﬁndings (eg, the value
of reducing the number of injections per day or not
gaining weight) can be established. For a patient with
type 2 diabetes who requires treatment intensiﬁcation
after failure of basal insulin in combination with oral
agents, combination injectable therapy is recommended,
consisting of either adding a GLP-1 RA or bolus insulin
to the current therapy, or switching to premixed
insulin.40 Intensifying treatment by adding bolus insulin
usually requires three additional injections a day at meal-
times on top of the current basal insulin (minimum
once daily), resulting in a regimen with a minimum of
four injections daily. Alternatively, the patient could add
a GLP-1 RA to the current basal insulin (minimum 2
daily injections) or switch to premixed insulin, which
requires a total of two injections per day. According to
this study, moving from a treatment with four injections
per day to that with only two injections per day, was
valued at US$50 per month in North America and
South America, and US$48 per month in Europe,
assuming that all other treatment aspects are the same.
Another example that illustrates the applicability of the
ﬁndings from this study refers to weight gain associated
with insulin therapy. Although many diabetes treatments
cause weight gain, some have shown to be weight
neutral or even to result in weight loss. For a given treat-
ment that provides a weight loss of 3 kg compared to a
treatment with no weight change, all other things
remaining equal, patients would value this at US$64 per
month in North America, US$37 per month in South
America, and US$60 per month in Europe. These exam-
ples of the applicability of the value of individual treat-
ment attributes could potentially be combined for a
more in-depth assessment and exploration of the WTP
for type 2 diabetes treatments that provide improve-
ments in several of the attributes examined in this study.
There are a number of potential limitations of the
study, associated with the methodology. As many patients
may not regularly experience out-of-pocket expenditure
for their healthcare requirements (eg, patients in
Europe), the WTP estimates may differ from the value
patients would pay for improvements in clinical
outcomes in real-life situations. Hence the relative
importance of each attribute might be a more relevant
outcome of this study than the individual WTP
estimates. Purchasing power is the preferred way of com-
paring monetary values across countries, but it is also
introducing an additional uncertainty. Although the
discrete choice experiments methodology is designed to
restrict the potential for strategic answers from respon-
dents, there is still potential for stated preferences
within each scenario presented in the study to differ
from those made by the same individual in a real-life
situation. Recruitment was through online panels requir-
ing respondents to have an email address and an
adequate degree of computer literacy, which may have
introduced selection bias. It is also acknowledged that,
despite clear description in the questionnaire, some
respondents may yet have interpreted the out-of-pocket
expense as a one-off payment, rather than a monthly
outlay. Furthermore, the questionnaire is self-reported,
without validation of clinical characteristics by health-
care providers, resulting in potential for recall bias.
In conclusion, the present study has shown people
with type 2 diabetes value improved clinical outcomes,
and reduced burden of preparing and injecting insulin.
Reducing HbA1c and the number of major hypogly-
cemic events were attributes that generated some of the
higher WTP values, but the burden associated with the
preparation of dosing insulin was also considered
important. Patient perceptions of the risks associated
with intensifying insulin treatment may result in non-
adherence and act as barriers to achieving treatment
goals. Understanding patients’ preferences can help to
develop optimal treatment approaches for individuals
with type 2 diabetes. This in turn could lead to improved
clinical control through improved treatment adherence
resulting in better clinical outcomes.
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